[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335118-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335118-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-nectin-family-ligands-pvrl2-and-pvr-in-cancer-immunology-and-immunotherapy","The Nectin family ligands, PVRL2 and PVR, in cancer immunology and immunotherapy","","Immunotherapy has become a key cancer treatment, yet its efficacy varies across tumor types and responses to current immune checkpoint inhibitors remain limited, with many patients developing acquired resistance. This review examines PVRL2 and PVR, members of the Nectin and Nectin-like Molecules family, describing how these cell-cell adhesion ligands on tumor and antigen-presenting cells engage PVRIG and TIGIT on T and NK cells to suppress antitumor immunity. The article analyzes the DNAM-1 axis mechanisms and their relevance across solid and hematologic cancers, highlighting therapeutic opportunities.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-nectin-family-ligands-pvrl2-and-pvr-in-cancer-immunology-and-immunotherapy/335118/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-nectin-family-ligands-pvrl2-and-pvr-in-cancer-immunology-and-immunotherapy/335118.png","ImageObject",300,407,{"name":42,"@type":43},"Oliver","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are PVRL2 and PVR, and where are they expressed in cancer?","Question",{"text":63,"@type":64},"PVRL2 (Nectin-2/CD112) and PVR (Necl-5/CD155/TAGE4) are Nectin-family ligands. They are predominantly expressed on tumor cells and antigen-presenting cells.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which immune receptors do PVRL2 and PVR bind to, and what is the consequence?",{"text":68,"@type":64},"PVRL2 binds to PVRIG and PVR binds to TIGIT on T and NK cells. These interactions suppress antitumor immunity by acting as immune checkpoint factors.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is the DNAM-1 axis considered important for developing therapies?",{"text":72,"@type":64},"The immunomodulatory mechanism involving the PVRL2-PVRIG and PVR-TIGIT bindings, termed the DNAM-1 axis, is described as complex. Understanding it is presented as essential for designing novel therapeutic strategies, potentially in combination with existing treatments.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335118,1790216026,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":4},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","TYPE Review  \nPUBLISHED 02 August 2024  \nDOI 10.3389/fimmu.2024.1441730  \nOPEN ACCESS  \nEDITED BY  \nNoha Mousaad Elemam,  \nUniversity of Sharjah, United Arab Emirates  \nREVIEWED BY Peng Xu,  \nYangzhou University, China Wei Wang,  \nUniversity of Wisconsin-Madison, United States  \n*CORRESPONDENCE Sudipto Ganguly  \n [sgangul8@jhmi.edu](sgangul8@jhmi.edu)  \nRECEIVED 31 May 2024  \nACCEPTED 22 July 2024  \nPUBLISHED 02 August 2024  \nCITATION  \nMurakami K and Ganguly S (2024) The Nectin family ligands, PVRL2 and PVR, in cancer immunology and immunotherapy.  \nFront. Immunol. 15:1441730 .  \ndoi: 10.3389/fimmu.2024.1441730  \nCOPYRIGHT  \n© 2024 Murakami and Ganguly. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nThe Nectin family ligands, PVRL2 and PVR, in cancer immunology and immunotherapy  \nKosuke Murakami and Sudipto Ganguly*  \nThe Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, United States  \nIn recent years, immunotherapy has emerged as a crucial component of cancer treatment. However, its efﬁcacy remains limited across various cancer types, highlighting unmet needs. Poliovirus receptor-related 2 (PVRL2) and Poliovirus receptor (PVR) are members of the Nectin and Nectin-like Molecules family, known for their role as cell-cell adhesion molecules. With the development of immunotherapy, their involvement in tumor immune mechanisms as immune checkpoint factors has garnered signiﬁcant attention. PVRL2 and PVR are predominantly expressed on tumor cells and antigen-presenting cells, binding to PVRIG and TIGIT, respectively, which are primarily found on T and NK cells, thereby suppressing antitumor immunity. Notably, gynecological cancers such as ovarian and endometrial cancers exhibit high expression levels of PVRL2 and PVR, with similar trends observed in various other solid and hematologic tumors. Targeting these immune checkpoint pathways offers a promising therapeutic avenue, potentially in combination with existing treatments. However, the immunomodulatory mechanism involving these bindings, known as the DNAM-1 axis, is complex, underscoring the importance of understanding it for developing novel therapies. This article comprehensively reviews the immunomodulatory mechanisms centered on PVRL2 and PVR, elucidating their implications for various cancer types.  \nKEYWORDS  \ncancer immunotherapy, DNAM1, immune checkpoint inhibitor, PVR, PVRIG, PVRL2, TIGIT  \n1 Introduction  \nIn recent years, immunotherapy has become a new treatment modality for solid and non-solid cancers (1–3) . It has become an essential pillar of cancer treatment, along with surgery, chemotherapy, and radiation therapy. Among immunotherapies, anti-CTLA4 and anti-PD-1/PD-L1 antibodies are the most common immune checkpoint inhibitors (ICIs) for solid tumors (3) . Starting with the 2011 FDA approval of the anti-CTLA4 antibody, Ipilimumab, for metastatic melanoma (4), the anti-PD-1 antibodies (e.g., nivolumab, pembrolizumab, dostarlimab) and the anti-PD-L1 antibodies (e.g. , atezolizumab,  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \ndurvalumab, avelumab) have been FDA-approved for a variety of cancers (5) . ICIs are a very promising treatment, sometimes affecting dramatically in cases that would have otherwise had no effective treatment (5) . On the other hand, the therapeutic efﬁcacy of existing ICIs is limited, and even in potentially effective carcinomas, response rates are limited to 20-40%(6) . In addition, there are many cases in which acquired resistance develops during the treatment ","cbCaic0JBcLGz185","https://ap.wps.com/l/cbCaic0JBcLGz185","pdf",1279657,13,"English","# 1 Introduction\n# 2 PVRL2 and PVR as the Nectin and Nectin-like molecule family","[{\"question\":\"What are PVRL2 and PVR, and where are they expressed in cancer?\",\"answer\":\"PVRL2 (Nectin-2/CD112) and PVR (Necl-5/CD155/TAGE4) are Nectin-family ligands. They are predominantly expressed on tumor cells and antigen-presenting cells.\"},{\"question\":\"Which immune receptors do PVRL2 and PVR bind to, and what is the consequence?\",\"answer\":\"PVRL2 binds to PVRIG and PVR binds to TIGIT on T and NK cells. These interactions suppress antitumor immunity by acting as immune checkpoint factors.\"},{\"question\":\"Why is the DNAM-1 axis considered important for developing therapies?\",\"answer\":\"The immunomodulatory mechanism involving the PVRL2-PVRIG and PVR-TIGIT bindings, termed the DNAM-1 axis, is described as complex. Understanding it is presented as essential for designing novel therapeutic strategies, potentially in combination with existing treatments.\"}]","The Nectin family ligands, PVRL2 and PVR, in cancer immunology and immunotherapy | PDF",1790009728,33]